NasdaqGS - Delayed Quote USD

scPharmaceuticals Inc. (SCPH)

4.4900 +0.1400 (+3.22%)
At close: April 26 at 4:00 PM EDT
4.4900 0.00 (0.00%)
After hours: April 26 at 4:20 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
13,593.0000
13,593.0000
--
--
--
Cost of Revenue
3,811.0000
3,811.0000
--
--
--
Gross Profit
9,782.0000
9,782.0000
--
--
--
Operating Expense
65,178.0000
65,178.0000
36,157.0000
25,823.0000
29,933.0000
Operating Income
-55,396.0000
-55,396.0000
-36,157.0000
-25,823.0000
-29,933.0000
Net Non Operating Interest Income Expense
-3,019.0000
-3,019.0000
-2,099.0000
-2,526.0000
-2,272.0000
Other Income Expense
3,605.0000
3,605.0000
1,418.0000
315.0000
-4.0000
Pretax Income
-54,810.0000
-54,810.0000
-36,838.0000
-28,034.0000
-32,209.0000
Net Income Common Stockholders
-54,810.0000
-54,810.0000
-36,838.0000
-28,034.0000
-32,209.0000
Diluted NI Available to Com Stockholders
-54,810.0000
-54,810.0000
-36,838.0000
-28,034.0000
-32,209.0000
Basic EPS
-1.36
-1.42
-1.30
-1.02
-1.31
Diluted EPS
-1.36
-1.42
-1.30
-1.02
-1.31
Basic Average Shares
36,637.6890
38,513.7470
28,358.5020
27,351.7300
24,568.8970
Diluted Average Shares
36,637.6890
38,513.7470
28,358.5020
27,351.7300
24,568.8970
Total Operating Income as Reported
-55,396.0000
-55,396.0000
-36,157.0000
-25,823.0000
-29,933.0000
Total Expenses
68,989.0000
68,989.0000
36,157.0000
25,823.0000
29,933.0000
Net Income from Continuing & Discontinued Operation
-54,810.0000
-54,810.0000
-36,838.0000
-28,034.0000
-32,209.0000
Normalized Income
-54,810.0000
-54,810.0000
-36,838.0000
-28,034.0000
-32,209.0000
Interest Income
5,104.0000
5,104.0000
1,203.0000
49.0000
315.0000
Interest Expense
8,123.0000
8,123.0000
3,302.0000
2,575.0000
2,587.0000
Net Interest Income
-3,019.0000
-3,019.0000
-2,099.0000
-2,526.0000
-2,272.0000
EBIT
-46,687.0000
-46,687.0000
-33,536.0000
-25,459.0000
-29,622.0000
EBITDA
-46,061.0000
-46,061.0000
-33,068.0000
-25,021.0000
-29,223.0000
Reconciled Cost of Revenue
3,811.0000
3,811.0000
--
--
--
Reconciled Depreciation
626.0000
626.0000
468.0000
438.0000
399.0000
Net Income from Continuing Operation Net Minority Interest
-54,810.0000
-54,810.0000
-36,838.0000
-28,034.0000
-32,209.0000
Normalized EBITDA
-46,061.0000
-46,061.0000
-33,068.0000
-25,021.0000
-29,223.0000
12/31/2020 - 11/17/2017

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

MIST Milestone Pharmaceuticals Inc.
1.5400
-3.14%
 
LIFE aTyr Pharma, Inc.
1.5700
-1.57%
 
LYRA Lyra Therapeutics, Inc.
4.7200
-8.70%
 
IKT Inhibikase Therapeutics, Inc.
1.7100
-8.06%
 
MGTX MeiraGTx Holdings plc
4.8000
+1.91%
 
ITOS iTeos Therapeutics, Inc.
10.80
+1.89%
 
MCRB Seres Therapeutics, Inc.
0.8250
+11.08%
 
SAVAW Cassava Sciences, Inc.
0.4200
+35.48%
 
NGNE Neurogene Inc.
29.96
+0.30%
 
FULC Fulcrum Therapeutics, Inc.
7.14
+0.14%